15.41 +0.02 (0.12%)
After hours: 4:11PM EDT
|Bid||11.80 x 900|
|Ask||16.29 x 3100|
|Day's Range||15.25 - 15.56|
|52 Week Range||11.47 - 17.99|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||10.42|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. It would also reference the effect on exacerbations based on data from the InforMing the PAthway of COPD Treatment (IMPACT) study. Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said, “Many patients with COPD continue to experience exacerbations despite taking dual bronchodilator therapies.
Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Innoviva is one of United States’s large-cap stocks that saw some insider selling over the past three months, with insidersRead More...
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allscripts ...
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
BRISBANE, Calif.-- -- Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million, or $0.49 per diluted share. The Company intends to prepay $110 million of its Term B Loan. Innoviva, Inc. today reported financial results for the second quarter ended June 30, ...
On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).
Analysts are bullish on these following companies: Innoviva, Jazz Pharmaceuticals, Cardlytics. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. AnalysingRead More...
GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease .
Innoviva, Inc. (INVA) (“Innoviva”) today announced the appointment of Geoffrey Hulme as interim Principal Executive Officer effective May 21, 2018. Mr. Hulme has a 25 year career in finance and investment management with a record of creating and maximizing shareholder value. Prior to joining Innoviva, Mr. Hulme served as the owner and manager of Steel Valley Capital LLC and Steel Valley Advisors LLC, a Registered Investment Adviser.
Stock Monitor: Innoviva Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on INSYS Therapeutics, Inc. (NASDAQ: INSY ) ("INSYS"). ...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.
GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base. The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease .